(24/7 MARKET NEWS) – Clene Inc. (NASDAQ: CLNN) reported, this morning, new results from exploratory analyses including delayed time to key clinical progression events in people living with amyotrophic lateral sclerosis (ALS) who were treated with CNM-Au8(R) in the HEALEY ALS Platform Trial over the 6-months of the double-blind period.
Highlights include;
• CNM-Au8 associated with a 74% lower risk (lower hazard ratio) of ALS clinical worsening, which included death, non-invasive ventilation >22 hours per day, tracheostomy, or feeding tube placement (p = 0.035)
• CNM-Au8 associated with a 98% lower risk of death or permanent assisted ventilation (p= 0.028)
• CNM-Au8 associated with a 74% lower risk of feeding tube placement (p= 0.035)
• CNM-Au8 associated with a 63% lower risk of initiation of assisted ventilation (p= 0.058)
• CNM-Au8 treatment was well-tolerated without significant safety concerns
Clene is trading at $1.47, up $0.17 (+13.07%), on 2.2 million premarket shares.
Its 52-week trading range is $0.87 to $5.13. It made a big one day run on February 13.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
